Fibroscan Scans for Liver Scarring During Immunotherapy in Liver Cancer
Tests Fibroscan liver scans to predict immunotherapy response in adults with liver cancer.
Plain-language title generated from the registry record
Registry title: Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma
Key facts
- Where
- Tanta, EgyptSee the site
Where in Egypt
- Tanta University HospitalsTanta, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tanta University
- Trial code
- NCT06960863
- Record updated
- 7 May 2025
- Original description
The goal of this prospective cohort study is to evaluate the role of transient elastography (Fibroscan) in predicting the response of immunotherapy in advanced Hepatocellular carcinoma (HCC) patients.Read full original descriptionShow less
Transient Elastography (Fibroscan) for Evaluation of Immunotherapy Response in Hepatocellular Carcinoma.
The goal of this prospective cohort study is to evaluate the role of transient elastography (Fibroscan) in predicting the response of immunotherapy in advanced Hepatocellular carcinoma (HCC) patients.
Researchers will predict the response to 6 months of HCC immunotherapy regarding improvement of the degree of liver fibrosis, development of liver decompensation, complications, survival, and mortality.
Participants will undergo history-taking, clinical examination, laboratory investigations, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, Triphasic CT abdomen with contrast or MRI (for evaluation of tumor site, size and number), and Fibroscan examination at baseline and follow-up after 6 months.
Inclusion: Patients with confirmed advanced HCC (Diagnosed by two imaging modalities or liver biopsy) eligible for immunotherapy; Patients with preserved liver function (compensated Child-Pugh A if there is underlying cirrhosis); Patients with performance status ≤2 at staging work-up; absence of high-risk stigmata for bleeding on upper endoscopy, e.g. properly treated oesophageal varices and no history of variceal bleeding, in order to minimise bleeding risk.
Exclusion: Prior locoregional therapy or liver transplantation; Vascular disorders, arterial hypertension, and risk of variceal bleeding; Severe autoimmune disorders; Child-Pugh class C patients; Patients with performance status >2 at staging work-up; Patients who lost follow-up; Pregnant or breastfeeding women; Unwilling to participate in our study.